The primary objective of this study is to evaluate the efficacy of atezolizumab plus tiragolumab and atezolizumab plus placebo as first-line treatment in recurrent/metastatic PD-L1-positive squamous cell carcinoma of the head and neck on the basis of the confirmed objective response rate. This evidence concerns the gene CD274 and squamous cell carcinoma.